CARAFATE

This brand name is authorized in United States. It is also authorized in New Zealand.

Active ingredients

The drug CARAFATE contains one active pharmaceutical ingredient (API):

1	Sucralfate UNII XX73205DH5 - SUCRALFATE
	Sucralfate forms an ulcer adherent complex with the proteinaceous exudate of the ulcer site. This property enables sucralfate to form a protective barrier over the ulcer lesion giving sustained protection against the penetration and action of gastric acid, pepsin and bile.
	Read more about Sucralfate

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CARAFATE Tablet	MPI, US: SPL/Old	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A02BX02	Sucralfate	A Alimentary tract and metabolism → A02 Drugs for acid related disorders → A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) → A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
Discover more medicines within A02BX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NZ	Medicines and Medical Devices Safety Authority	3655
US	FDA, National Drug Code	17856-0170, 58914-170, 58914-171